Osteotec Limited, a medical device manufacturer and distributor, is now the exclusive distributor of SI-BONE, Inc.’s iFuse Implant System® in the United Kingdom and Ireland.
Osteotec and SI-BONE Announce Partnership
2 min read Premium comments
#osteotec#siboneSecondary#ifuseimplantsystem
Osteotec and SI-BONE recently announced the strategic partnership. The agreement went into effect April 1, 2024. Per the press release, it is anticipated that the partnership will “contribute to substantial increases in sales and revenue and accelerate growth.” Together, the companies will merge their expertise and technologies to boost marketing opportunities, foster productivity, and drive healthcare outcomes.
SI-BONE Vice President, International Neville Lorimer expressed excitement about the partnership. In the press release, Lorimer stated, “We are excited about working with Osteotec to expand our footprint in the UK and Ireland.”
Lorimer continued, “With the assistance of Osteotec’s talented commercial team and extensive industry knowledge, we will be able to accelerate our strategic objective of providing superior patient outcomes in these markets.”
San Jose, California-based SI-BONE is focused on developing minimally invasive surgical solutions for the sacroiliac joint. Per the press release, the iFuse Implant System is intended for “sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis.” The iFuse Implant Systems are “designed to provide immediate stabilization of the SI joint, aiming to enhance the quality of life and offer lasting relief.”
OTW spoke with Osteotec Sales and Marketing Director Dean Stockwell about the partnership. Stockwell explained, “We believe this strategic partnership will enhance our ability to reach more surgeons and patients who can benefit from SI-BONE’s life-changing treatment. By investing in commercial expansion across the UK and Ireland, we aim to extend the iFuse Implant System’s availability and impact.”
He continued, “Our shared goals with this partnership are to build on our commercial capabilities to accelerate the growth of the iFuse Implant System across the UK and Ireland and increase its market share. We also want to continue to provide best-in-class educational opportunities for our customers to deepen their understanding of SI joint pain and the benefits of SI-BONE’s treatment solutions.”
Osteotec is based in Newbury, United Kingdom. For more than 30 years, Osteotec has been a supplier to both private healthcare sectors and the National Health Service. The company has a number of exclusive distribution agreements in the United Kingdom with leading orthopedic companies.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.